Changchun High-Tech Industry's subsidiary, GenSci143, has obtained approval for the overseas production of injectable drugs for clinical trials.

Changchun High-Tech Industry (000661.SZ) announced that its subsidiary Changchun Ginsai Pharmaceutical Co., Ltd. (referred to as "Ginsai Pharmaceutical") recently received a written notification from the U.S. Food and Drug Administration (FDA) that the clinical trial application for injection of GenSci143 by Ginsai Pharmaceutical has been approved. GenSci143 is a bispecific antibody-drug conjugate (BsADC) targeting B7-H3 and PSMA independently developed by Ginsai Pharmaceutical, with potential dual therapeutic effects of targeted chemotherapy and tumor immunotherapy. It is classified as a Class 1 biologic drug for the treatment of various advanced solid tumors such as prostate cancer and lung cancer.